Se ha denunciado esta presentación.
Se está descargando tu SlideShare. ×

Biotech Companies Attracting More Investors, Including Corporates

Ad

Biotech Companies Attracting
More Investors, Including
Corporates
By: James Ahern Laidlaw

Ad

Biotech Companies Attracting More Investors,
Including Corporates
Previously a managing director with Aegis Capital, James...

Ad

Biotech Companies Attracting More Investors,
Including Corporates
Investments in biotech are growing, according to an annu...

Ad

Eche un vistazo a continuación

1 de 4 Anuncio
1 de 4 Anuncio
Anuncio

Más Contenido Relacionado

Anuncio

Biotech Companies Attracting More Investors, Including Corporates

  1. 1. Biotech Companies Attracting More Investors, Including Corporates By: James Ahern Laidlaw
  2. 2. Biotech Companies Attracting More Investors, Including Corporates Previously a managing director with Aegis Capital, James Ahern is currently the head of capital markets at Laidlaw & Company. Working from the New York Laidlaw office, James "Jimmy" Ahern focuses on raising capital for companies in healthcare and related sectors, including biotechnology.
  3. 3. Biotech Companies Attracting More Investors, Including Corporates Investments in biotech are growing, according to an annual report by Crunchbase. The report, which evaluated funding rounds by biotech companies in 2018, revealed that biotech startups globally raised close to $29 billion that year. This was a significant rise from the $19 billion in funding raised in 2017 and about $15 billion in 2016. These numbers include funds raised in the seed, early, and late stages, as well as funding raised in corporate rounds.
  4. 4. Biotech Companies Attracting More Investors, Including Corporates The report also showed that corporate investors are investing more in biotech companies than before. In total, corporate investors participated in 138 funding rounds, an increase from 122 in 2017. While they did not pump money into most biotech deals, where they did, they invested large sums. Altogether, rounds with a corporate venture capitalist on board or as the lead were valued at $8 billion. Likewise, not all corporate players invested equally in biotech startups. Some, like Novartis, invested way more with an aggregate of $730 million in 15 rounds.

×